Home > Boards > Free Zone > All Trading - Technical > General Stock Ideas

Ombow, Humanigen's Phase 3 is to have

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
gfp927z Member Profile
 
Followed By 60
Posts 22,172
Boards Moderated 70
Alias Born 03/22/05
160x600 placeholder
gfp927z   Wednesday, 07/01/20 01:12:11 AM
Re: ombowstring post# 17491
Post # of 17561 
Ombow, Humanigen's Phase 3 is to have an interim analysis soon, on 1/2 of the patients in the trial (1/2 of 238), so a big enough sample to provide a good indication of the drug's efficacy. The stock is moving in anticipation of this interim analysis.

While the CYDY severe trial is also having an interim analysis soon, it will only be on 50 patients (12.5% of the total patients that the trial will eventually enroll). 'Spiritof76' points out that this will not be nearly enough to get a good gauge of the Leronlimab's efficacy. He also points out several reasons (see below) to doubt Leronlimab's potential for the severe patients, and sees the mild/moderate trial as the best hope for showing efficacy. An interim analysis of at least 100 patients is what is really needed, which might be forthcoming later in the Summer. The full severe trial won't reach completion until approx Spring of 2021.



>>> The data one the mild to moderate will be ready in the second half of the month, at least that is what I think. I doubt the severe data will be available this month at all. Even if it is ready IL6 blockers have already been studied in severe covid 19 patients and they did not work.

The Mild to Moderate date is only 75 to 80 patients strong and a phase 2/3 study. I am hoping that data looks great. Likely additional study will have to follow.

The Severe study has 50 patients in the interim data, or N12.5% out of 390 to 400 patients. That data is worthless, even if it shows promise. I hope they delay until they have at least 100 patients if not N50% as is typical. <<<



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156630414


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156580279



This is what he's referring to -

https://www.nejm.org/doi/full/10.1056/NEJMc2011117












Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist